Multicenter phase 1 trial of allogeneic BCMA-targeting CAR T cells for relapsed or refractory multiple myeloma
ALLO-715 is a first-in-class, allogeneic, anti-BCMA CAR T cell therapy engineered to abrogate graft-versus-host disease and minimize CAR T rejection. The multicenter phase 1 UNIVERSAL trial evaluated ALLO-715 after lymphodepletion with an anti-CD52 antibody (ALLO-647)-containing regimen in 43 patients with relapsed or refractory multiple myeloma (RRMM). Interim analysis of the trial found that grade ≥ 3 adverse events were reported in 38 patients (88.0%). Response was seen in 24 patients (55.8%). Among patients receiving 320 x 106 CAR T cells and fludarabine-, cyclophosphamide- and ALLO-647-based lymphodepletion regimen (n=24) response was seen in 17 patients (70,8%) including 6 (25%) with a complete/stringent complete response. Median duration of response was 8.3 months. The authors conclude that these initial results support the feasibility and safety of allogeneic CAR T cell therapy for RRMM.